Summarized by Masters of Longevity from Nature - Biotechnology.
Liver-targeted base editing cut ANGPTL3 >90% and lowered lipids in models.
Key Takeaways
- A single dose reduced circulating ANGPTL3 protein by over 90%.
- ANGPTL3 inactivation lowered LDL-C by about 40–50% in models.
- Triglycerides were reduced roughly 50–70% but human efficacy is unproven.
